RxDoctor Payments Data

Ravinderan Krishnan, MD

Ophthalmology · Corpus Christi, TXNPI 1952393373

Payments from drug & device makers

$8,287in general payments, 2019–2025

Across 145 payments — averaging $57.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Rxsight Inc$2K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • AbbVie$867
  • Biotissue Holdings Inc.$447
  • Ivantis, Inc$164
  • plus $654 from 16 others

What the payments were for

  • Travel & lodging$1,60419%
  • Food & beverage$6,49878%
  • Education$180%
  • Gifts$681%
  • Entertainment$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,287 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$541,109
Medicare patients
912
Services billed
4,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine73$87,526
LumiganBimatoprost77$36,494
Prednisolone Acetate503$18,227
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol142$15,617
Ketorolac Tromethamine494$14,995
XiidraLifitegrast12$12,869
RocklatanNetarsudil Mesylat/Latanoprost28$12,350
Travoprost98$12,270
Cyclosporine17$12,079
MoxifloxacinMoxifloxacin Hcl330$10,310
CombiganBrimonidine Tartrate/Timolol47$9,777
Latanoprost1,103$9,772
Timolol Maleate418$7,857
VyzultaLatanoprostene Bunod16$6,859
Brimonidine Tartrate272$6,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$867$139,318218 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$19$19,72828 claims
AlconSimbrinza$2,419$3,96421 claims
Thea Pharma Inc.Iyuzeh$17$3,12411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →